Physician profile
Daniel T Sines
NPI 1508028218
$81,073.99
in general payments reported to CMS, 2019-2025
18 companies · $22K in 2025
The $22K reported for 2025 was more than what 97% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $2,931 · 2021: $10K · 2022: $9,542 · 2023: $16K · 2024: $19K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Honoraria: $14K · Consulting Fee: $5,100 · Travel and Lodging: $4,849 · Food and Beverage: $3,006 · Entertainment: $62.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31,025.00 |
| Honoraria | $13,975.00 |
| Consulting Fee | $5,100.00 |
| Travel and Lodging | $4,848.80 |
| Food and Beverage | $3,005.98 |
| Entertainment | $62.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $40,914.52 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $38,671.66 | 2020-2023 | Tepezza |
| Carl Zeiss Meditec USA, INC. | $292.59 | 2021 | |
| Biotissue Holdings INC. | $237.13 | 2021-2025 | |
| Tarsus Pharmaceuticals, INC. | $174.16 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $108.10 | 2019-2025 | Idose, Idosetr, Istent Infinite |
| Bausch & Lomb Americas INC. | $98.88 | 2022-2025 | Miebo, Stellaris, Vyzulta |
| Genentech USA, INC. | $86.78 | 2019-2025 | Susvimo, Vabysmo |
| Abbvie INC. | $85.92 | 2022-2025 | |
| Optos, INC. | $62.38 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Kala Pharmaceuticals, INC. | $60.07 | 2021-2022 | |
| Rxsight INC | $59.53 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $55.47 | 2019 | |
| Novartis Pharmaceuticals Corporation | $42.11 | 2019 | |
| Alcon Vision LLC | $38.03 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $37.53 | 2021-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $33.69 | 2019 | |
| Dompe US, INC. | $15.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.